TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06748001: An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study

Sponsor: Blueprint Medicines Corporation · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,072,960

Rescue Site Savings

+$3,346,560

Unlock Full NCT06748001 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06748001 Rescue Dossier →